Ruggie Capital Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Ruggie Capital Group’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-270	Closed	-$14K	–	122
2019 Q2	$14K	Hold	270	–	–	0.02%	113
2019 Q1	$15K	Sell	270 -180	-40%	-$9.7K	0.02%	133
2018 Q4	$19K	Hold	450	–	–	0.01%	256
2018 Q3	$31K	Hold	450	–	–	0.02%	159
2018 Q2	$26K	Hold	450	–	–	0.01%	217
2018 Q1	$25K	Hold	450	–	–	0.01%	186
2017 Q4	$25K	Buy	+450	New	+$25.4K	0.02%	180

Other funds holding BIB

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

SBIA

Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

CAL

Capital Analysts LLC Fort Washington, Pennsylvania $3.81B AUM 15.52% 1-Year Est. Return

Ruggie Capital Group's BIB Position: Q3 2019 in Review

Ruggie Capital Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2019, closing a stake of 270 shares — an estimated $14K sold.

Ruggie Capital Group first reported a position in BIB in Q4 2017 and held it in 7 quarters. The position peaked at $31K in Q3 2018. 25 funds tracked by Wall St. Rank hold BIB as of Q3 2019.

Ruggie Capital Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2019 after selling out during the quarter.
Ruggie Capital Group sold 270 ProShares Ultra NASDAQ Biotechnology shares in Q3 2019, an estimated $14K.
Ruggie Capital Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2017 and held it in 7 quarters.
Ruggie Capital Group's ProShares Ultra NASDAQ Biotechnology position peaked at $31K in Q3 2018.
25 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2019.

Based on Ruggie Capital Group's 13F filing for Q3 2019, filed 6 Nov 2019.